Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. - Wikidata - wikimedia - TriplyDB

Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells.

Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells.

http://www.wikidata.org/entity/Q35556981

about

GSK-3 as potential target for therapeutic intervention in cancer Advances in targeting signal transduction pathways Calcium/calmodulin-dependent protein kinase II (CaMKII) phosphorylates Raf-1 at serine 338 and mediates Ras-stimulated Raf-1 activation.Extract of Pleurotus pulmonarius suppresses liver cancer development and progression through inhibition of VEGF-induced PI3K/AKT signaling pathway Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.Hormone Therapy plus mTOR Inhibitors in the Treatment of Endometrial Carcinoma.Mtor-Fanconi Anemia DNA Damage Repair Pathway in Cancer.HIV Protease Inhibitors Sensitize Human Head and Neck Squamous Carcinoma Cells to Radiation by Activating Endoplasmic Reticulum Stress.Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells.Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes.MiR-205 determines the radioresistance of human nasopharyngeal carcinoma by directly targeting PTEN.MEK2 regulates ribonucleotide reductase activity through functional interaction with ribonucleotide reductase small subunit p53R2.Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine Mechanistic or mammalian target of rapamycin (mTOR) may determine robustness in young male mice at the cost of accelerated aging.Analysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptor-Positive, HER2-Negative Early Breast Cancer.Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.Recent progress in genetics of aging, senescence and longevity: focusing on cancer-related genes.A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia Drug resistance and the role of combination chemotherapy in improving patient outcomes.Rapamycin extends life- and health span because it slows aging.The AKT inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated AKT-1 and synergizes with conventional chemotherapy Chaetoglobosin K inhibits tumor angiogenesis through downregulation of vascular epithelial growth factor-binding hypoxia-inducible factor 1α.GSK-3β: a key regulator of breast cancer drug resistance.Inhibition of GSK-3β activity can result in drug and hormonal resistance and alter sensitivity to targeted therapy in MCF-7 breast cancer cells.Inside out: targeting NHE1 as an intracellular and extracellular regulator of cancer progression.Mechanisms of Metastatic Tumor Dormancy.Silibinin sensitizes chemo-resistant breast cancer cells to chemotherapy.Genetic and epigenetic cancer chemoprevention on molecular targets during multistage carcinogenesis.K562 cell proliferation is modulated by PLCβ1 through a PKCα-mediated pathway.Midkine confers Adriamycin resistance in human gastric cancer cells.The relationships between snail1 and estrogen receptor signaling in breast cancer cells.Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: implications for the treatment of human liver cancer.Regulation of cell survival by sphingosine-1-phosphate receptor S1P1 via reciprocal ERK-dependent suppression of Bim and PI-3-kinase/protein kinase C-mediated upregulation of Mcl-1.Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells.Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells.

P2860

Q27013811-E2CC032B-7E17-4827-BD31-4B1C6989A67C Q27686983-508839FA-4E2D-4CB7-9C41-08F69D03E49B Q27865262-AA852337-0C9D-48B9-9878-AAB299044372 Q28481696-7DBA7F8C-DB71-42D3-8765-1009D6454E7C Q34103963-01A57262-237B-4AD9-B164-E0DD8CAED80B Q34307356-B9E9C8EE-B3BC-4D4A-A714-ED7365DFEE12 Q34571141-05B35A17-DC19-41E2-AE80-255C44AE036C Q35000084-41321C9E-30C8-4E87-9936-2B3AD1422781 Q35620220-A6769E2D-F0EE-4B26-A45D-4CF8373EDBB9 Q35640228-4B8B1E5B-6058-46C2-B596-074810D7692F Q35640301-AC89AFF1-D6C4-4021-B67E-EDA0F632853E Q35857643-8D928C60-DAAB-497A-AF3D-BA3B07A196A4 Q35974749-8BC83CED-5F72-410D-8FA2-8C5854C456EE Q36304116-8155E64A-9775-4A11-977A-8A02AD7F5DBB Q36556350-2954F4E7-9830-4210-8BEF-13321DB6FB99 Q36736362-36B235FC-8FEB-4BC8-9A52-1FB472D1B023 Q36804506-FA58868F-139B-454C-9157-5482349E62E4 Q36862768-E94021B6-973C-4BFB-9713-27D862778434 Q36926098-2B3636C4-DDE9-4C4E-8F99-C8CB0FE98606 Q36926129-3135A72F-2488-450D-89E4-B0206136179C Q36999509-D02A052C-1F4F-4D23-9946-A53E1990EC86 Q37228766-5CC87B16-6829-4264-A609-B1016EADF4C2 Q37299276-FB3F3A85-7D83-4070-931B-F02C963312CF Q37305672-F033EF7B-6F45-4921-B606-FA4757D08A65 Q37692574-4896893C-A068-4846-8C32-A17F7F4C11AE Q37692593-AB8BE3AF-219D-44A2-A8E6-5B185EE192F7 Q38068566-DC6674C7-5392-4601-93AE-BC444F83D229 Q38559618-A641B53F-4FEC-4808-993C-262557BF54A2 Q38724100-CAD5E906-9206-4D79-9333-DDC0C1AD9EAF Q38931011-61691ED7-79B8-416A-9C57-9602C9512280 Q39154752-CE1C0CC6-C7E7-4723-9C6F-8D93D04C633F Q39350211-BC1CF43D-5798-4600-873D-7DDE60734BA5 Q39401164-3E54DB53-A071-4B9D-8D3F-F34153857ED9 Q41832567-61B5D192-867B-49B7-936F-B351813AE3A9 Q42854212-8E71C6D8-926A-4857-BB3A-2650A6D0B89F Q44174238-EE6BC55F-B2D2-4E1A-A31C-FE59C3C31441 Q47110143-B6FDA5EC-DD74-43A2-B772-D7E2CA4617C1

P2860

Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells.

http://www.wikidata.org/entity/Q35556981

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Involvement of Akt and mTOR in ...... iation in breast cancer cells.

@ast

Involvement of Akt and mTOR in ...... iation in breast cancer cells.

@en

type

label

Involvement of Akt and mTOR in ...... iation in breast cancer cells.

@ast

Involvement of Akt and mTOR in ...... iation in breast cancer cells.

@en

prefLabel

Involvement of Akt and mTOR in ...... iation in breast cancer cells.

@ast

Involvement of Akt and mTOR in ...... iation in breast cancer cells.

@en

P1433

Q35556981-48C56EF8-021C-4473-B314-B72C77B7676A

P1476

Q35556981-6E372868-2D7E-40EF-BACF-13C7C0312B59

P2093

Q35556981-20C49843-F0B9-4EAB-BAEC-B66E14730D33

Q35556981-4A0BCB85-561A-49B9-93D9-0CC0BD3ADB47

Q35556981-59ABE373-D0DD-4477-82C0-CE45A0DD3925

Q35556981-623AB59F-1009-4BD4-A8AB-05CD8D86EBDF

Q35556981-70667AF1-0D81-4837-A934-49DEE09A4DA6

Q35556981-70C9E022-31EE-4813-8C1A-554829464164

Q35556981-73D71620-C7B4-4B8E-9722-65B601D2DC8E

Q35556981-74247D4E-1E3F-4B0B-869E-B710A054E55D

Q35556981-ADC12D5F-D16E-474A-83E8-FE0C12109C57

Q35556981-C63B2482-34DB-45E5-AD1C-99FF6D16C44D

P2860

Q35556981-01C66B62-8A40-4A89-8FCC-508A4101685E

Q35556981-05B87E59-7569-49D3-B553-387BCE600BCC

Q35556981-0A84B6F6-3A7A-40F8-8993-6A1CD1F60C47

Q35556981-0CA4638C-7CD4-4F42-9871-73F11628FFDB

Q35556981-0E65CECF-8E10-4CC9-B01B-5581105AE263

Q35556981-10D52C86-1A26-4C85-8DE7-E83C7356D77C

Q35556981-1362A908-393C-4431-A840-39B4FDEB98FF

Q35556981-1698A9D6-1CF9-4E6A-934F-EE0CFB200C26

Q35556981-1BC792A1-6656-4F6C-8904-4253967FD0A7

Q35556981-229980CF-65E6-4AD2-8B94-BE59178943E1

P304

Q35556981-30A770FF-7F1A-47C8-8B89-E73AC83D19FB

P31

Q35556981-561B85A2-3D8C-4ABA-85C4-B6048308A9A4

P356

Q35556981-209C7649-2D00-409B-AE71-E09EBDC9B41B

P433

Q35556981-49417E2F-398D-4239-B491-87D89C7CB95A

P478

Q35556981-9B222598-EFAA-4835-8BCE-6E9571C8B0B3

P577

Q35556981-5C63DCDC-5352-4294-9911-B5AF1E8CA746

P5875

Q35556981-BE8028DB-A419-462D-B4F2-BFC68E593C35

P698

Q35556981-D48494C1-7D68-4671-AC88-AB64B7830F96

P921

Q35556981-E53D855B-4220-45B1-A7C3-008B56D242F9

P932

Q35556981-3D201A29-3C16-48F3-908F-72622731C461

P356

P1433

P1476

Involvement of Akt and mTOR in ...... iation in breast cancer cells.

@en

P2093

Alberto M Martelli

http://www.w3.org/2001/XMLSchema#string

Ellis W T Wong

http://www.w3.org/2001/XMLSchema#string

Ferdinando Nicoletti

http://www.w3.org/2001/XMLSchema#string

Franca Stivala

http://www.w3.org/2001/XMLSchema#string

James A McCubrey

http://www.w3.org/2001/XMLSchema#string

Linda S Steelman

http://www.w3.org/2001/XMLSchema#string

Lucio Cocco

http://www.w3.org/2001/XMLSchema#string

Lyudmyla B Drobot

http://www.w3.org/2001/XMLSchema#string

Massimo Libra

http://www.w3.org/2001/XMLSchema#string

Patrick Navolanic

http://www.w3.org/2001/XMLSchema#string

P2860

Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a)

Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation

Regulation of p53 function and stability by phosphorylation

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

Phosphorylation and regulation of Raf by Akt (protein kinase B)

A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1

DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2

Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate

Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling

Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha

P304

3003-3015

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/CC.10.17.17119

http://www.w3.org/2001/XMLSchema#string

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2011-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51597801

http://www.w3.org/2001/XMLSchema#string

P698

21869603

http://www.w3.org/2001/XMLSchema#string

P921

P932

3218601

http://www.w3.org/2001/XMLSchema#string